Galaxy Biopharmaceutical

Galaxy Biopharmaceutical (Nanjing Galaxy Biopharmaceutical) is a Chinese biotechnology company focused on the development of novel therapeutics for oncology and immuno-oncology. As a subsidiary of the publicly traded Galaxy Biological Investment, the company leverages its expertise in both small molecule discovery and antibody engineering. Its lead clinical candidate, C-005, is a third-generation EGFR tyrosine kinase inhibitor currently undergoing Phase 1 evaluation for the treatment of advanced non-small cell lung cancer. In addition to its internal drug pipeline, the company has established a prominent position in the preclinical services market through its HuGEMM humanized mouse platform. Developed in partnership with Crown Bioscience, these humanized knock-in models are used by pharmaceutical companies globally to test checkpoint inhibitors and other immuno-oncology agents. Galaxy Biopharmaceutical's integrated approach combines innovative drug development with advanced translational research tools.